| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | HAO2 |
| Uniprot No | Q9NYQ3 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-351aa |
| 氨基酸序列 | SLVCLTDFQAHAREQLSKSTRDFIEGGADDSITRDDNIAAFKRIRLRPRY LRDVSEVDTRTTIQGEEISAPICIAPTGFHCLVWPDGEMSTARAAQAAGI CYITSTFASCSLEDIVIAAPEGLRWFQLYVHPDLQLNKQLIQRVESLGFK ALVITLDTPVCGNRRHDIRNQLRRNLTLTDLQSPKKGNAIPYFQMTPIST SLCWNDLSWFQSITRLPIILKGILTKEDAELAVKHNVQGIIVSNHGGRQL DEVLASIDALTEVVAAVKGKIEVYLDGGVRTGNDVLKALALGAKCIFLGR PILWGLACKGEHGVKEVLNILTNEFHTSMALTGCRSVAEINRNLVQFSRL |
| 预测分子量 | 55 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于HAO2重组蛋白的3篇示例参考文献(内容为模拟概括，非真实文献)：
1. **《Expression and Purification of Recombinant HAO2 in E. coli for Functional Studies》**
- 作者：Zhang, L. et al. (2018)
- 摘要：研究报道了通过大肠杆菌表达系统高效重组表达人源HAO2蛋白的优化方法，采用His标签纯化技术获得高纯度蛋白，并验证其体外催化羟基酸氧化的酶活性。
2. **《Structural Insights into HAO2-Mediated Lipid Metabolism by X-ray Crystallography》**
- 作者：Kim, S. & Patel, R. (2020)
- 摘要：通过X射线晶体学解析了小鼠HAO2重组蛋白的三维结构，揭示了其底物结合域的关键氨基酸残基，为理解HAO2在脂质代谢中的作用机制提供结构基础。
3. **《HAO2 Recombinant Protein Attenuates Hepatic Steatosis in Obese Mouse Models》**
- 作者：Wang, Y. et al. (2021)
- 摘要：研究发现注射重组HAO2蛋白可显著改善高脂饮食诱导的小鼠肝脏脂肪堆积，表明HAO2通过调控脂肪酸氧化途径具有潜在治疗非酒精性脂肪肝的应用价值。
注：以上文献名称及内容为模拟生成，实际研究需通过PubMed/SCI-Hub等平台检索真实文献。
HAO2 (Hydroxyacid Oxidase 2) is a peroxisomal enzyme encoded by the HAO2 gene, primarily involved in fatty acid metabolism. It catalyzes the oxidation of long-chain 2-hydroxy fatty acids to corresponding 2-keto acids, a critical step in the α-oxidation pathway that processes branched-chain fatty acids and bile acid intermediates. This function positions HAO2 as a key player in lipid homeostasis and energy production.
The recombinant HAO2 protein is engineered through molecular cloning techniques, typically expressed in bacterial (e.g., E. coli) or mammalian cell systems to ensure proper folding and post-translational modifications. Its recombinant form enables detailed study of enzymatic kinetics, substrate specificity, and interactions with metabolic regulators. Structural analyses using X-ray crystallography have revealed conserved motifs in its (S)-2-hydroxy-acid oxidase domain, providing insights into catalytic mechanisms.
Research links HAO2 dysregulation to metabolic disorders. Reduced HAO2 expression has been observed in non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes, correlating with impaired lipid processing. Conversely, elevated levels in certain cancers suggest context-dependent roles in cell proliferation. Recent studies explore HAO2's potential as a therapeutic target, particularly for rare peroxisomal disorders like Refsum disease where phytanic acid accumulation occurs.
Pharmaceutical interest focuses on developing HAO2 modulators to address metabolic syndrome components. However, challenges persist in understanding tissue-specific isoform functions and developing selective inhibitors without off-target effects on related oxidases. Current applications extend to diagnostic biomarker development and in vitro toxicology screens for drug-induced steatosis.
×
